Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1509889 | 0.91 | CA2 (0.35) | CYP2D6OPRK1 | |
| SCHEMBL27228693 | 0.73 | MMP2 (0.44) | — | |
| SCHEMBL4297055 | 0.73 | MMP2 (0.44) | — | |
| SCHEMBL7262682 | 0.71 | KEAP1 (0.43) | — | |
| SCHEMBL13936947 | 0.60 | GPBAR1 (0.46) | — | |
| SCHEMBL8998762 | 0.60 | LMNA (0.40) | — | |
| SCHEMBL28374258 | 0.60 | BCAT2 (0.33) | — | |
| SCHEMBL11072331 | 0.59 | HPGD (0.43) | — | |
| SCHEMBL7748074 | 0.59 | CA2 (0.44) | — | |
| SCHEMBL7279348 | 0.59 | SSTR4 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897721-B2 | Cyclic peptide compositions for treatment of sexual dysfunction | PALATIN TECHNOLOGIES, INC. (US) | 2011-03-01 | — | — | US | disclosed |
| US-20100121027-A1 | Cyclic Peptide Compositions for Treatment of Sexual Dysfunction | PALATIN TECHNOLOGIES, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| US-7176279-B2 | Cyclic peptide compositions and methods for treatment of sexual dysfunction | PALATIN TECHNOLOGIES, INC. (US) | 2007-02-13 | — | — | US | disclosed |
| EP-1667700-A2 | CYCLIC PEPTIDE COMPOSITIONS AND METHODS FOR TREATMENT OF SEXUAL DYSFUNCTION | Palatin Technologies, Inc. (US) | 2006-06-14 | — | — | EP | disclosed |
| WO-2005014617-A2 | CYCLIC PEPTIDE COMPOSITIONS AND METHODS FOR TREATMENT OF SEXUAL DYSFUNCTION | PALATIN TECHNOLOGIES, INC. (US) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100121027-A1 | Cyclic Peptide Compositions for Treatment of Sexual Dysfunction | VIP, GNRHR, NPR1 | CYP2D6 4277/4885OPRK1 1001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.